Archives

Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

In 2023, an estimated 39.9 million people globally were living with HIV, there were 1.3 million people who acquired HIV, and 630,000 people died from AIDS-related illnesses worldwide (World Health Organization [WHO]). Among people living with HIV (PLWH), morbidity and mortality is increasingly driven by co-infections. The risk of tuberculosis (TB) progressing from latent to active disease is estimated to be up to 20 times greater in PLWH than among those without HIV, with fatality rates of 16-35%. For HIV-associated hepatitis, WHO estimates that 2.6 million PLWH are also living with Hepatitis B Virus (HBV) and 2.75 million are also living with Hepatitis C Virus (HCV) worldwide.

Health Topics: 
HIV

Request Funding to Explore Controlled Release of HIV Vaccines

Grant Source: 
NIH/NIAID

NIAID’s new notice of funding opportunity (NOFO) Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01, Clinical Trial Not Allowed) supports research to advance controlled-release strategies for HIV vaccines that aim to elicit protective and durable broadly neutralizing responses and antiviral T-cell/innate responses.

Health Topics: 
HIV

MATRIX Technology Accelerator Domain 1 Prevention Challenges: Overcoming Impediments to HIV Prevention

Grant Source: 
USAID

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) through the United States President’s Emergency Plan for AIDS Relief (PEPFAR), under the terms of Cooperative Agreement #AID-OAAA-17-00015. The contents are the responsibility of PATH and do not necessarily reflect the views of MATRIX, USAID, PEPFAR, or the United States government.

Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.

MATRIX Prevention Challenges RFA

Grant Source: 
USAID

The MATRIX Prevention Challenges RFA is now open. The objective of this funding opportunity is to support the development of solutions to specific challenges facing the field of HIV prevention. Investigators and institutions from Kenya, South Africa, Zimbabwe, United States (US), European Union (EU), or United Kingdom (UK), are invited to apply to this request for applications (RFA) sponsored by MATRIX: A USAID Project to Advance the Research and Development of Innovative HIV Prevention Products for Women. 

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this FOA is to provide investigators working on the development of novel therapeutic products for HIV and HIV-associated co-infections (hepatitis B virus, hepatitis C virus, and Mycobacterium tuberculosis) with a mechanism to request NIAID DAIDS preclinical services to fill gaps in their product development efforts and facilitate the advancement of promising therapeutics from bench to clinics.

Health Topics: 
HIV
Viral Hepatitis

Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

Grant Source: 
NIH/NIAID

Clinical experience for HIV treatment and prevention has demonstrated that adherence to a drug regimen schedule is a significant factor in the success of the HIV treatment regime and/or prevention strategies. Effective treatment of HIV-infected individuals requires strict adherence to a multi-component regimen of antiretroviral agents taken at least daily for the remainder of a patient’s life. Non-adherence can lead to emergence of drug-resistance and loss of therapeutic effectiveness. Among people living with HIV, morbidity and mortality is increasingly driven by co-infections, such as tuberculosis (TB) and hepatitis B, where the compliance and completion of prolonged multidrug regimens are significant factors in treatment success.

Effective prevention requires that the inhibitor be present at the right time, place, and concentration to stop HIV transmission and acquisition. Although many factors (social, behavioral, and individual preference) can influence adherence, the use of drug delivery systems to provide for a longer therapeutic exposure or window of protection and/or less frequent administration may improve their consistent use, reduce dosing intervals, and potentially improve adherence to the drug regimens.

Development of safe, effective, and well-tolerated sustained release (SR)/long acting (LA) products and strategies that maintain consistent and effective drug levels in plasma and target tissues for longer periods of time is critical for successful treatment and prevention of HIV and HIV-associated co-infections.

Health Topics: 
HIV
Tuberculosis

Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV

Grant Source: 
HRSA

This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression.

Health Topics: 
HIV

Pages